Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Chi Ching Mak"'
Autor:
Steven Cha, Emily Creger, Betty Tam, Chi-Ching Mak, Brian Eastman, Lauren Sitts, Sunil Kc, Carine Bossard, Heekyung Chung, John Duc Nguyen, Timothy Phalen
Publikováno v:
Cancer Research. 80:P3-13
Aberrant activation of the Wnt signaling pathway is associated with tumorigenesis, relapse/chemoresistance, and distance metastasis in TNBC. SM08502 is a novel, oral, small-molecule pan-CLK inhibitor that has been shown to potently inhibit the Wnt si
Autor:
Eric Wang, Jose Mario Bello Pineda, Won Jun Kim, Sisi Chen, Jessie Bourcier, Maximilian Stahl, Simon J. Hogg, Jan Phillipp Bewersdorf, Cuijuan Han, Michael E. Singer, Daniel Cui, Caroline E. Erickson, Steven M. Tittley, Alexander V. Penson, Katherine Knorr, Robert F. Stanley, Jahan Rahman, Gnana Krishnamoorthy, James A. Fagin, Emily Creger, Elizabeth McMillan, Chi-Ching Mak, Matthew Jarvis, Carine Bossard, Darrin M. Beaupre, Robert K. Bradley, Omar Abdel-Wahab
Publikováno v:
Cancer Cell. 41:164-180.e8
Therapy resistance is a major challenge in the treatment of cancer. Here, we performed CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to identify genomic determinants of drug response. Our screens uncover a selec
Autor:
Elizabeth A. McMillan, Carine Bossard, Emily Creger, Carsten Merkwirth, Raffaella Pippa, Matthew Jarvis, Krishna Sriram, Melinda Pedraza, Maureen Ibanez, Deepti Bhat, Carolyn Lai, Josh Stewart, Brian Eastman, Chi-Ching Mak, Michael A. White, Darrin Beaupre
Publikováno v:
Cancer Research. 82:3928-3928
Dysregulated alternative pre-mRNA splicing (AS) is commonly associated with human malignancies, producing pathological proteomes that underlie disease initiation, progression, and therapeutic resistance. The CDC2-like kinases (CLKs) and dual-specific
Autor:
Kiev S. Ly, Andrew Richard Hudson, Christine Hoffmaster, James T. Limberis, J. Guy Breitenbucher, Richard Barido, De Michael Chung, Yingzhuo Yan, Gary Anderson, Vincent J. Santora, Dany Gitnick, Dong Lee, Brett C. Bookser, Anne Danks, Robert E. Petroski, Graeme Freestone, Varsha Gupta, Clifford Cabebe, Andrew Morse, Michael R. Kennedy, Kristen Sebring, Zachary W. Yoder, Douglas Zook, Marco Peters, Chih-Kun Chai, Joel Renick, Jim Na, Theresa A. Almos, Shouzhen Xia, Ali Tabatabaei, John Nikpur, Samantha Sevidal, Stephine Chow, Mi Chen, Jillian Basinger, Chris L. Bellows, Lindsay Heger, David Neul, Jenny Wen, Brittany Masatsugu, Nicola J. Broadbent, Alan P. Kaplan, Chi Ching Mak
Publikováno v:
Bioorganicmedicinal chemistry letters. 30(14)
A strategy to conformationally restrain a series of GlyT1 inhibitors identified potent analogs that exhibited slowly interconverting rotational isomers. Further studies to address this concern led to a series of azetidine-based inhibitors. Compound 2
Autor:
David Neul, Andrew Morse, Joel Renick, Brittany Masatsugu, Chi Ching Mak, James T. Limberis, Dany Gitnick, Zachary W. Yoder, Michael R. Kennedy, Kiev S. Ly, Samantha Sevidal, Richard Barido, Robert E. Petroski, Graeme Freestone, Clifford Cabebe, Jillian Basinger, Vincent J. Santora, Christine Hoffmaster, Chris L. Bellows, Yingzhuo Yan, Mi Chen, De Michael Chung, John Nikpur, Kristen Sebring, Jenny Wen, Ali Tabatabaei, Brett C. Bookser, Theresa A. Almos, Andrew Richard Hudson, J. Guy Breitenbucher, Chih-Kun Chai, Dong Lee, Lindsay Crickard, Anne Danks, Varsha Gupta, Marco Peters, Alan P. Kaplan, Jim Na, Nicola J. Broadbent, Stephine Chow, Douglas Zook
Publikováno v:
Journal of Medicinal Chemistry. 61:6018-6033
We report here the identification and optimization of a novel series of potent GlyT1 inhibitors. A ligand design campaign that utilized known GlyT1 inhibitors as starting points led to the identification of a novel series of pyrrolo[3,4- c]pyrazoles
Autor:
Hadi Falahatpisheh, Maryam Dehghani, Jane Morrow, Catherine Tsao, Steven Dorrow, Josh Stewart, Carine Bossard, Brian Eastman, Chi-Ching Mak, Karamjeet Pandher, Michael A. White
Publikováno v:
Molecular Cancer Therapeutics. 20:P250-P250
Proteome diversification through extensive pre-mRNA alternative splicing (AS) is a fundamental aspect of cell fate determination and tissue specialization. The CDC2-like kinases (CLK1-4) and the dual specificity tyrosine phosphorylation regulated kin
Autor:
Carine Bossard, Emily Creger, Elizabeth A. McMillan, Carsten Merkwirth, Maureen Ibanez, Deepti Bhat, Josh Stewart, Brian Eastman, Chi-Ching Mak, Vishal Deshmukh, Michael A. White
Publikováno v:
Molecular Cancer Therapeutics. 20:P242-P242
A monumental challenge facing cancer therapy is the vast mechanistic diversity of tumors among and even within cancer patients. This severely limits the number of patients that respond to any given therapy and the durability of responses that do occu
Autor:
Emily Creger, Chi-Ching Mak, Michael A. White, Elizabeth A. McMillan, Darrin M. Beaupre, Carine Bossard, Brian Eastman
Publikováno v:
Blood. 138:2950-2950
Mutations in spliceosomal genes are one of the most common classes of somatic alterations in patients with Myelodysplastic Syndrome (MDS) and occur across the entire spectrum of myeloid malignancies, including 10‒25% of patients with acute myeloid
Autor:
Yusuf Yazici, Abdullah Ghias, Joseph Cahiwat, Dellamary Luis A, Charlene F. Barroga, John Duc Nguyen, V. Deshmukh, Emily Creger, Maureen Ibanez, Chiao-Wen Chen, Heekyung Chung, Betty Tam, Sunil Kumar Kc, Kevin Chiu, Steven Cha, Long Do, Timothy Phalen, Shawn Cho, Jackie Nguyen, Josh Stewart, Brian Eastman, Carine Bossard, John Hood, Chi Ching Mak
Publikováno v:
Cancer letters. 473
The Wnt/β-catenin signaling pathway is aberrantly activated in colorectal (CRC) and many other cancers, and novel strategies for effectively targeting it may be needed due to its complexity. In this report, SM08502, a novel small molecule in clinica
Autor:
Josh Stewart, Brian Eastman, Lauren Sitts, Heekyung Chung, Chi Ching Mak, Steven Cha, Timothy Phalen, Sunil Kc, Carine Bossard, Chu-Chiao Wu
Publikováno v:
Cancer Research. 80:6401-6401
Dysregulation of the cyclin D-CDK4/6-RB signaling axis is implicated in HR+ breast cancer (BC). While CDK4/6 inhibitors such as palbociclib (Palbo) have shown efficacy in this cancer type, overcoming resistance to these agents is an unmet need for pa